The DelveInsight’s Pemphigus Vulgaris market report provides an in-depth overview of Pemphigus Vulgaris, historical and anticipated epidemiology, and Pemphigus Vulgaris market trends in the 7MM. The report also examines current Pemphigus Vulgaris treatment practices/algorithms, market drivers, market barriers, unmet medical needs, SWOT analysis to identify the best opportunities, and the market’s underlying potential.
Some Key Highlights from the Pemphigus Vulgaris Market Report
- As per DelveInsight Pemphigus Vulgaris epidemiology insights, the total diagnosed prevalent cases was estimated to be 42,419 in 7MM in 2020.
- In the United States, the Pemphigus Vulgaris diagnosed prevalence was observed over 14,000 in 2020, out of which the mild cases accounted for the highest number of cases followed by severe and moderate.
- Among the EU5 countries, Germany had the highest Pemphigus Vulgaris diagnosed prevalence, while France had the lowest in 2020.
- Rituxan (Rituximab) was approved by the US Food and Drug Administration in June 2018 for Pemphigus Vulgaris treatment. MabThera (Rituximab) was also authorized by the European Commission in March 2019 for the treatment of individuals with moderate to severe Pemphigus Vulgaris.
- Rilzabrutinib (Principia Biopharma) and Efgartigimod (Argenx BVBA) are the most anticipated emerging therapies to hit the Pemphigus Vulgaris treatment market. Another new drug, TPM203 (Topas Therapeutics), is being tested in a phase I clinical trial in Pemphigus Vulgaris patients at seven German sites.
- Key pharmaceutical companies working diligently in the development of therapies for Pemphigus Vulgaris treatment include Principia Biopharma, Argenx BVBA, Topas Therapeutics, and others.
To get more insights request sample @ Pemphigus Vulgaris Market Size
The Pemphigus Vulgaris market report covers current treatment methods, developing pharmaceuticals, market share of specific therapies, as well as the current and predicted 7MM Pemphigus Vulgaris market size between 2018 and 2030.
Pemphigus Vulgaris is a severe autoimmune and intraepithelial illness characterized by flaccid blisters and skin and mucous membrane erosions. It is characterized histologically by acantholysis and is caused by circulating desmoglein-reactive autoantibodies directed towards the surfaces of keratinocyte cells.
Pemphigus Vulgaris Epidemiology Segmentation
- Pemphigus Vulgaris Total Diagnosed Prevalent Cases
- Pemphigus Vulgaris Gender-Specific Diagnosed Prevalent Cases
- Pemphigus Vulgaris Age-Specific Diagnosed Prevalent Cases
- Pemphigus Vulgaris Severity-Specific Diagnosed Prevalent Cases
Learn more about epidemiology @ Pemphigus Vulgaris Epidemiology
Pemphigus Vulgaris Treatment Landscape
The current treatment options for Pemphigus Vulgaris includes:
- Corticosteroids (prednisolone)
- Immunosuppressant (azathioprine and mycophenolate)
- Cyclophosphamide, methotrexate, dapsone
- Intravenous immunoglobulins
- Immunoadsorption, therapeutic plasma exchange, extracorporeal photochemotherapy
The Pemphigus Vulgaris treatment market is being driven by increased awareness of pemphigus disease and its healthcare. Furthermore, having better treatment facilities requires access to education and information on all kinds of pemphigus.
The prevalence rate of Pemphigus Vulgaris has been observed to be increasing, boosting the expansion of the Pemphigus Vulgaris treatment industry, and total Pemphigus Vulgaris cases in the 7MM will increase from 2018 to 2030. As a result, the PV therapies market will continue to grow.
Get more details about PV @ Pemphigus Vulgaris Treatment Market
Pemphigus Vulgaris Pipeline Therapies and Key Companies
- Rilzabrutinib: Principia Biopharma
- Efgartigimod: Argenx BVBA
- TPM203: Topas Therapeutics
- Approval of MabThera/Rituxan
- Increasing awareness
- Rising prevalence rates
- Updated diagnostic and treatment guidelines
Pemphigus Vulgaris Market Barriers
- Difficulties in developing new treatment
- Lack of disease understanding
- Disease diversity
- Limited approved and emerging therapies
Scope for the Report
Coverage: 7MM (the US, EU5 (the UK, Germany, Italy, Spain and France) and Japan)
Study Period: 2018-30
Pemphigus Vulgaris Key Companies: Principia Biopharma, Argenx BVBA, Topas Therapeutics, among others.
Pemphigus Vulgaris Key Pipeline Therapies: Rilzabrutinib and Efgartigimod , TPM203 , and others.
Pemphigus Vulgaris Segmentation: By Geography, Pemphigus Vulgaris drugs
Analysis: Comparative and conjoint analysis of Pemphigus Vulgaris emerging therapies
Tools Used: SWOT Analysis
Table of Contents
|2.||Executive Summary of Pemphigus Vulgaris (PV)|
|3.||Pemphigus Vulgaris (PV) Market Overview at a Glance|
|4.||Disease Background and Overview: Pemphigus Vulgaris (PV)|
|5.||Pemphigus Vulgaris Case Reports|
|6.||Pemphigus Vulgaris Epidemiology and Patient Population|
|7.||Pemphigus Vulgaris United States Epidemiology|
|8.||Pemphigus Vulgaris EU5 Epidemiology|
|9.||Pemphigus Vulgaris Japan Epidemiology|
|10.||Pemphigus Vulgaris Current Treatment and Medical Practices|
|11.||Pemphigus Vulgaris Unmet needs|
|12.||Pemphigus Vulgaris Marketed Drugs|
|13.||Pemphigus Vulgaris Emerging Drugs|
|14.||Pemphigus Vulgaris (PV): 7MM Market Analysis|
|15.||Pemphigus Vulgaris United States Market Outlook|
|16.||Pemphigus Vulgaris EU-5 countries: Market Outlook|
|17.||Pemphigus Vulgaris Japan Market Outlook|
|18.||Pemphigus Vulgaris Market Drivers|
|19.||Pemphigus Vulgaris Market Barriers|
|21.||Pemphigus Vulgaris Reimbursement and market access|
Know more about report offering @ Pemphigus Vulgaris Market Outlook
Get comprehensive historical and forecast analysis of Bullous Pemphigoid Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Nihon Pharmaceutical, Regeneron Pharmaceuticals, Sanofi, Akari Therapeutics, among others.
Get comprehensive historical and forecast analysis of Familial Hypercholesterolemia Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Amgen, Regeneron Pharmaceuticals, Esperion Therapeutics, Novartis, Sanofi, LIB Therapeutics, NeuroBo Pharmaceuticals and Arrowhead Pharmaceuticals.
DelveInsight’s “Early Cardiogenic Shock (CS) – Market Insights, Epidemiology, and Market Forecast-2030” report.
Get comprehensive historical and forecast analysis of Extracorporeal Shock Wave Therapy Devices Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as EMS Electro Medical Systems S.A., BTL Corporate, Dornier MedTech GmbH, and Zimmer MedizinSysteme GmbH, Siemens AG, Boston Scientific Corporation, NCELER MEDICAL LTD, Guangzhou Longest Science & Technology Co.
DelveInsight’s ‘Hypofibrinogenemia – Market Insights, Epidemiology, and Market Forecast—2030’ report.
DelveInsight’s “Diffuse cutaneous systemic sclerosis (dcSSc) – Market Insights, Epidemiology, and Market Forecast-2030” report.
DelveInsight’s “Systemic Juvenile Idiopathic Arthritis (SJIA) – Market Insights, Epidemiology, and Market Forecast-2030” report.
Get comprehensive historical and forecast analysis of Gene and Cell Therapies Targeting CNS Disorders Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Novartis, Helixmith, BrainStorm Cell Therapeutics, Corestem, Ferrer Internacional others.
Get comprehensive historical and forecast analysis of Intrahepatic Cholangiocarcinoma Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Incyte Corporation, Roche, Delcath Systems, Basilea Pharmaceutica, Agios Pharmaceuticals, Bayer, Qed Therapeutics, among others.
Get comprehensive historical and forecast analysis of Lamellar Ichthyosis Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Timber Pharmaceuticals, Krystal Biotech, Galderma among others.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance.
Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.